Antitumor activity of lorlatinib by RECIST response in patients with soft tissue disease.
DISEASE
Bar color represents best overall response for all sites of disease by NANT response criteria v2.0. Dashed line represents 30% change from baseline to obtain PR or greater in soft tissue sector of response, 

Kaplan-Meier plots of progression-free survival (A) and overall survival (B) by cohort.

